• No results found

CURRICULUM VITAE 2012, March

N/A
N/A
Protected

Academic year: 2021

Share "CURRICULUM VITAE 2012, March"

Copied!
6
0
0

Loading.... (view fulltext now)

Full text

(1)

CURRICULUM VITAE

2012, March

OVERVIEW INFORMATION

Name: MARHOUM EL FILALI Kamal

Date and birthplace: July 16 , 1958 in Casablanca, Morocco Sex: Male

Nationality: Moroccan Contact Information:

Business contact Personal details

Address: Faculté de Médecine Address: Résidence Mawlid 3, Appt C54 19, Rue Tarik Bnou Ziad Rue Abou Taour

20340 Casablanca, Morocco 20370 Casablanca, Morocco Tel: +212 5 22 48 20 66 Tel: +212 6 64 00 31 75

Fax: +212 5 22 20 43 33 Email: mefkamal@gmail.com Email: mefkamal@hotmail.com

Areas of expertise:

- Clinical experience in infectious diseases, particularly in care of HIV infected patients

- Quantification of antiretroviral drugs needs for HIV infected patients in Morocco

- HIV/AIDS prevention campaigns

- Evaluation of projects related to HIV/AIDS

- Education and training in the field of infectious diseases and HIV infection

Expertise related to HIV/AIDS - In Morocco:

Collaboration with the National AIDS Program

Commitment in the Moroccan experience of access to care and to antiretroviral therapy

Involvement in many national campaigns of prevention

In charge of HIV infection course in the Faculty of Medicine and Pharmacy of Casablanca

- At the international level :

Collaboration as consultant with UNAIDS (Republic of Congo in 2001)

Contribution to the development of an african consensus on antiretroviral therapy ( Dakar,

October 2000 )

Collaboration as consultant with WHO-EMRO (Republic of Yemen in 2007)

Collaboration as consultant with WHO-EMRO (Republic of Syria in 2009)

(2)

EDUCATION

1993 Certificate in Infected Patient Resuscitation Xavier Bichat University Paris, France

1993 Certificate in AIDS and retroviral diseases Xavier Bichat University, Paris, France

1993 Certificate ‘Résident Etranger du Collège de

Médecine des Hôpitaux de Paris’

Collège de Médecine des Hôpitaux de Paris, France

1989 Maghreban Certificate in Health Sciences

Pedagogy

Medical School, Casablanca, Morocco

1985 MD Medical School, Casablanca, Morocco

1976 – 1985 Medical School, Casablanca, Morocco

1976 Baccalaureate University of Bordeaux, France

1961 – 1976 Lycée Lyautey, Casablanca, Morocco

TRAINING

2010, October Antifungal preceptorship meeting. University of South Manchester, UK

2008, February Human Participants Protection Education for Research Teams

NIH, online course

2007, June Advanced Course on Security WHO, online course

2006, October GCP Training for investigators Roche, Casablanca, Morocco

2006, April Course on applied regression modelling University of Bristol and University of

Bern, Cape Town, South Africa

2005, July Course : Managing Procurement and Logistics of

HIV/AIDS Drugs and Related Supplies

World Bank Institute, Beirut, Lebanon

2002, July Training : Clinical studies monitoring Georges Pompidou European Hospital,

Paris, France

2001, March Atelier de mise à niveau des consultants

francophones

UNAIDS / WHO, Rabat, Morocco

2000, June The 2nd african workshop on antiretrovirals Dakar, Senegal

(3)

1997, May Symposium on HIV infection Mediterranean Society of Infectious and Parasitic Diseases, Cairo, Egypt

1996, March Course on Research Methodology Medical School, Casablanca, Morocco

1995, April Course on biostatistics Medical School, Casablanca, Morocco

1992 – 1993 Training : Intensive care Bichat-Claude Bernard Hospital, Paris,

France

1992, June Training : Digestive endoscopia Beaujon Hospital, Paris, France

1990, January Training : HIV infection care practice Bichat-Claude Bernard Hospital Paris,

France

WORKING EXPERIENCES

Permanent positions

Since 2011 Head of the Infectious Diseases Unit of Ibn Rochd University Hospital.

Since 2003 Member of the National Committee of Management of HIV infection (Ministry of Health)

Since 1997 Responsibility of ARVs quantification for the treatment of HIV infected patients in Morocco

Since 1997 In charge of HIV infection course in the Medical School of Casablanca

Since 1988 National Board member of ‘Association de Lutte Contre le Sida’

Since 1987 Physician in charge of management of HIV infection in the Infectious Diseases Unit of Ibn Rochd

University Hospital

Academic positions (Medical School of Casablanca)

1993 Professor of Infectious Diseases

1989 – 1993 Associate Professor 1986 – 1989 Assistant

1984 – 1986 Resident

(4)

INVOLVEMENT IN RESEARCH GRANTS

2002 – 2009 : Evaluation of Subcutaneous Proleukin® in a Randomized International Trial

(ESPRIT001), a randomized, open label, phase III, international study of subcutaneous recombinant interleukin-2 (Proleukin®) in patients with HIV-1 infection and CD4+ Cell Counts 300/mm3.

Site principal investigator: Hakima Himmich

The site of the Infectious Diseases Unit of Ibn Rochd University Hospital has enrolled 26 participants. Role in this research: Site co- investigator.

Research conducted by NIH

Financial support of NIH via Medical Research council in London Amount of money in the research grant: 103 664 GBP

2007 – 2011 : Study of Aldesleukin with and without Antiretroviral Therapy (STALWART :

ESPRIT002), a randomized, open-label, international study of subcutaneous recombinant interleukin-2 (Aldesleukin®) with and without concomitant antiretroviral therapy in patients with HIV-1 infection and CD4+ Cell Counts 300/mm3.

Site principal investigator: Hakima Himmich

The site of the Infectious Diseases Unit of Ibn Rochd University Hospital has enrolled 1 patient. Role in this research: Site co- investigator.

Research conducted by NIH

Financial support of NIH via Medical Research council in London Amount of money in the research grant: 3 162 GBP

2004 – 2007 : The SMART Study, a large, simple trial comparing the long-term clinical consequences

of two Strategies for Management of Anti-Retroviral Therapy (Protocol CPCRA 065), the drug

conservation strategy, a strategy aimed at conserving drugs through episodic use of antiretroviral treatment for the minimum time to maintain CD4+ cell count > 250 cells/mm3 versus the viral suppression strategy, a strategy aimed at suppressing viral load as much as possible, immediately following randomization and throughout follow up, irrespective of CD4+ cell count.

Site principal investigator: Hakima Himmich

The site of the Infectious Diseases Unit of Ibn Rochd University Hospital has enrolled 42 patients. Role in this research: Site investigator.

Research conducted by NIH

Financial support of NIH via Medical Research council in London Amount of money in the research grant: 307 382 USD

2010 - ongoing : Strategic Timing of AntiRetroviral Treatment (START), a randomized study to

determine whether immediate initiation of antiretroviral treatment (ART) is superior to deferral of ART until the CD4+ declines below 350 cells/mm3 in terms of morbidity and mortality in HIV-1 infected persons who are antiretroviral naïve with a CD4+ count above 500 cells/mm3.

The site of the Infectious Diseases Unit of Ibn Rochd University Hospital has included 21 patients and the enrolment is ongoing .

Role in this research: site principal investigator. Research conducted by NIH

Financial support of NIH via Medical Research council in London

Amount of money in the research grant: 775 600 USD (if the goal of 50 patients is reached)

2003-2007 : The Antiretroviral Treatment in Lower Income Countries

(ART-LINC) Collaboration to define prognosis of HIV-infected patients treated with HAART in

resource-poor settings, to compare experiences between different settings, delivery modes, and types of monitoring and to compare prognosis in resource-limited settings with that observed in industrialized nations.

Principal investigators: François Dabis, Mathias Egger, Mauro Schechter

The site of the Infectious Diseases Unit of Ibn Rochd University Hospital has participated with its cohort data.

Role in this research: clinic representative.

Research conducted by the University of Bern and the University of Bordeaux. Financial support of ANRS (France), CIHR (Canada) and NIH.

(5)

CONSULTATIONS AND PROGRAMMATIC EXPERIENCE

2011 Consultation on provider initiated HIV testing in

health care settings

Morocco Ministry of Health

2010 Consultation on HIV prophylaxis in case of sexual

violence

Morocco Ministry of Health

2006 Consultation on sharp waste management in hospital

(2nd phase) Morocco Ministry of Health

2004 Consultation on sharp waste management in hospital Morocco Ministry of Health

2003 Assessment and strengthening of referral centers for

HIV infection management

Morocco Ministry of Health

2001 Consultation on implementation of Access Initiative Republic of Congo UNAIDS

Since 2000 Coordinator of the education program for patients under ART Casablanca Morocco Infectious diseases unit/GSK foundation

2000 Contribution to the development of an African

consensus on ART

Dakar, Senegal

Since 1997 Consultation on ARVs procurement and supplying Morocco Ministry of Health

Since 1993 Collaboration with the National AIDS Program Morocco Ministry of Health

REGIONAL EXPERIENCE

March 2009 Syria : Consultation for the development of the GFATM proposal (WHO).

July 2007 Yemen : Consultation on ART for the NAP at ART sites of Sanaa and Aden (WHO).

2002 – 2007 Member of the steering group of Antiretroviral Therapy in Low Income Countries

(ART-LINC) collaboration

Since 1994 Morocco (Casablanca) : HIV Infection management

July 2001 Republic of Congo : Program Access of UNAIDS

1992 – 1993 France (Paris) : HIV infection management

1986 – 1991 Morocco (Casablanca) : Infectious diseases management

1984 – 1986 Morocco (Casablanca) : Internal medicine diseases management

(6)

PUBLICATIONS

1. Sodqi M, Marih L, Oulad Lahsen A, Bensghir R, Chakib A, Himmich H, Marhoum El Filali K. Causes de décès de 91 patients ayant une infection à VIH traités par des antirétroviraux. La Presse Médicale 2012, in press

2. Fane M, Oulad Lahsen A, Bakhatar A, Sodqi M, Marhoum El Filali K, Bahlaoui A, Chakib A. Aspergilose pulmonaire et infection à VIH (à propos de deux cas). Rev Pneumol Clin 2012, 68, 1 :36-9 3. Oulad Lahsen A, Rachidi T, Sodqi M, Abada R, Marhoum El Filali K. Paralysie faciale associée à la

leptospirose. Médecine et Maladies Infectieuses 2010; 40, 12 :716-717

4. Bakhouch K, Oulad-Lahcen A, Bensghir R, Blaghen M, Marhoum El Filali K, Ezzikouri S, Abidi O, Hassar M, Wakrim L. The prevalence of resistance-associated mutations to protease and reverse transcriptase inhibitors in treatment-naïve HIV1-infected individuals in Casablanca, Morocco. J Infect Dev Ctries 2009; 3(5):380-391

5. Kamal Marhoum El Filali, Hakima Himmich, Bloodstream infections. In : a guide to infection control

in hospital (fourth edition), R. Wenzel, G. Bearman, T. Brewer, J.P. Butzler (Eds). Brookline, 2008 ; 170-72.

6. Sandrine Loubière, Kamal Marhoum El Filali, Mustapha Sodqi, Anderson Loundou, Stéphane Luchini, Susan Cleary, Jean-Paul Moatti, Hakima Himmich. When to initiate highly active antiretroviral therapy in low resource settings : the Moroccan experience. Antiviral Therapy 2008 ; 13 : 241-51

7. Gaëlle Krikorian, Kamal Marhoum El Filali, Hakima Himmich. L’accès aux médicaments sous le nouveau régime de protection des brevets : cas du sida au Maroc. Knowledge Ecology Studies 2008 ; Vol.2 (Journal on-line : http://www.kestudies.org/)

8. ART-LINC Collaboration. Antiretroviral Therapy in Lower Income Countries (ART-LINC): International collaboration of treatment cohorts. Int J Epidemiol. 2005 Oct;34(5):979-86

9. Marih L, Sodqi M, Chakib A, Malmoussi M, Ouagari Z, Marhoum El Filali K, Himmich H. Kaposi cutané de forme tumorale: difficultés diagnostiques à propos d’un cas. Rev Maroc Med Santé 2005, 22, 1 : 44-47

10. Guide de la prise en charge de l’infection à VIH. Edité par le Ministère de la Santé, avec le soutien de l’OMS, sous la coordination du Pr Hakima Himmich, Rabat, 2004.

11. Malmoussi M, Zerouali K, Aajly L, Marhoum El Filali K, El Mdaghri N, Benbachir M, Himmich H. Méningite à méningocoque de l’adulte à propos de 117 cas. J Magh A Réa 2003, 43 : 262-5

12. Marih l, Sodqi M, Bensghir R, Marhoum El Filali K, Himmich H. Monitoring for efficacy of HAART in limited resource countries. Proceeding of International AIDS Conference, July 2002. 363-364. 13. Sodqi M, Marih L, Marhoum El Filali K, Himmich H. Infection with Mycobacterium tuberculosis

among HIV infected patients in Morocco. Proceedings of the XIV International AIDS Conference. July 2002. Barcelone.

14. Soussi-Abdallaoui M, El Kadioui-El Idrissi F, Chakib A, Marhoum El Filali K, Himmich H, Guessous-Idrissi N. Isospora belli au Maroc à propos de 4 nouveaux cas. Les Cahiers du Medecin 2002, 48 : 41-43.

15. Marhoum El Filali K, A Chakib, Himmich H. Accès aux antirétroviraux au Maroc. Bulletin S.M.S.M

1999, 1 : 17 – 21.

16. Marhoum El Filali K. Prise en charge d’un malade infecté par le VIH. Les cahiers du Médecin 1998 ;

11 : 25 – 27

17. Marhoum El Filali K. Prophylaxie de l’infection à VIH après une exposition accidentelle au sang. Les

cahiers du Médecin 1998 ; 11 : 28 – 29

18. Zahraoui M, Arssi M, Marhoum El Filali K, Chakib A, Himmich H. Tuberculose et infection par le VIH. Rev Maroc Med Santé 1992 , 14 ,1 : 7-12

References

Related documents

This report explores the influence of non-governmental organisations (NGOs) on the design of the climate compliance regime and how they work to promote climate performance among

The fitted values of the returns to schooling of each country of origin, which are obtained from the schooling quality production function, are then used to derive schooling

winning two-week program for high-school through graduate strings and pianists in rural Wisconsin, featuring guest performers and teachers such as Matt Haimovitz and the Ying

By affecting oscillatory activity in a predictable manner, transcranial brain stimulation may be used to shed light on the relationship between beta power

Background; A major dilemma is that pain free dental treatment using local anaesthesia (LA) is of main importance for avoiding dental fear and anxiety (DFA) at the same time

Although low adiponectin levels have been associated with PCOS which is mainly attributed to obesity among these patients, studies have also suggested that low adipo- nectin in PCOS

Antioxidant activity of tocopherols, tocotrienols, and gamma-oryzanol components from rice bran against cholesterol oxidation accelerated by

With respect to stock markets returns spill-over, United States is found to generate more than it contributes volatility of shocks to other countries, same was observed in the